129 related articles for article (PubMed ID: 11814539)
1. Melperone in the treatment of neuroleptic-resistant schizophrenia.
Meltzer HY; Sumiyoshi T; Jayathilake K
Psychiatry Res; 2001 Dec; 105(3):201-9. PubMed ID: 11814539
[TBL] [Abstract][Full Text] [Related]
2. A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jul; 62(1-2):65-72. PubMed ID: 12765745
[TBL] [Abstract][Full Text] [Related]
3. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
[TBL] [Abstract][Full Text] [Related]
4. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Psychiatry Res; 2010 Apr; 176(2-3):114-9. PubMed ID: 20199813
[TBL] [Abstract][Full Text] [Related]
5. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Hum Psychopharmacol; 2009 Jul; 24(5):415-22. PubMed ID: 19551763
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.
Delini-Stula A; Berdah-Tordjman D
J Psychiatr Res; 1996; 30(4):239-50. PubMed ID: 8905533
[TBL] [Abstract][Full Text] [Related]
8. Melperone in the treatment of schizophrenia.
Bjerkenstedt L
Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
12. Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia.
Röhricht F; Gadhia S; Alam R; Willis M
ScientificWorldJournal; 2012; 2012():512047. PubMed ID: 22566771
[TBL] [Abstract][Full Text] [Related]
13. A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward.
Härnryd C; Bjerkenstedt L; Gullberg B
Acta Psychiatr Scand Suppl; 1989; 352():40-7. PubMed ID: 2573240
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
15. Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study.
Pöldinger WJ
Neuropsychobiology; 1984; 11(3):181-6. PubMed ID: 6147789
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
17. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease.
Barbato L; Monge A; Stocchi F; Nordera G
Funct Neurol; 1996; 11(4):201-7. PubMed ID: 8934152
[TBL] [Abstract][Full Text] [Related]
18. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
19. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
20. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
Pickar D; Bartko JJ
Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
